Vigil Neuro Expands VGL101 Phase 1 Trial to Australia

June 8, 2022

Vigil Neuroscience Expands VGL101 Phase 1 Trial to Australia

– Received approval from the Human Research Ethics Committee in Australia to initiate a Phase 1 trial of VGL101 in healthy volunteers at doses above 20 mg/kg –

– Considering administration of a 30 mg/kg dose in VGL101 Phase 1 trial in the U.S. –

– Remain on track to report topline data from VGL101 Phase 1 healthy volunteer trial and to initiate the Phase 2 trial in ALSP in the fourth quarter of 2022 –

Full article: Vigil Neuroscience Expands VGL101 Phase 1 Trial to (globenewswire.com)